| 000 | 01543 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250515014752.0 | ||
| 264 | 0 | _c20060505 | |
| 008 | 200605s 0 0 eng d | ||
| 022 | _a1526-632X | ||
| 024 | 7 |
_a10.1212/01.wnl.0000196465.83423.ec _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aTosoni, A | |
| 245 | 0 | 0 |
_aIs protracted low-dose temozolomide feasible in glioma patients? _h[electronic resource] |
| 260 |
_bNeurology _cFeb 2006 |
||
| 300 |
_a427-9 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntineoplastic Agents, Alkylating _xadministration & dosage |
| 650 | 0 | 4 |
_aCentral Nervous System Neoplasms _xdrug therapy |
| 650 | 0 | 4 |
_aDacarbazine _xadministration & dosage |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 | _aDrug Administration Schedule |
| 650 | 0 | 4 | _aFeasibility Studies |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aGlioma _xdrug therapy |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aInfections _xetiology |
| 650 | 0 | 4 |
_aLymphopenia _xchemically induced |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aTemozolomide |
| 700 | 1 | _aCavallo, G | |
| 700 | 1 | _aErmani, M | |
| 700 | 1 | _aScopece, L | |
| 700 | 1 | _aFranceschi, E | |
| 700 | 1 | _aGhimenton, C | |
| 700 | 1 | _aGardiman, M | |
| 700 | 1 | _aPasetto, L | |
| 700 | 1 | _aBlatt, V | |
| 700 | 1 | _aBrandes, A A | |
| 773 | 0 |
_tNeurology _gvol. 66 _gno. 3 _gp. 427-9 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1212/01.wnl.0000196465.83423.ec _zAvailable from publisher's website |
| 999 |
_c16088928 _d16088928 |
||